Potassium Gluconate

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Belgium: Ultra-K; Poland: Kalium Gluconicum.

Latin America

Argentina: Gluco-K, Kaon, Potamkim; Mexico: Corpotasín.


Japan: Gluconsan K, Kalimozan.

Drug combinations


Potassium Gluconate: C~6~H~11~KO~7~. Mw: 234.25. D-Gluconic acid, monopotassium salt. CAS-299-27-4; CAS-35398-15-3 (monohydrate); CAS-526-95-4 (D-gluconic acid).

Pharmacologic Category

Replacement Preparations; Potassium Supplements. Oral Electrolyte Supplement. (ATC-Code: A12BA05).

Mechanism of action

Essential for conduction of nerve impulses in heart, brain, and skeletal muscle. Contraction of cardiac, skeletal and smooth muscles. Maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion.

Therapeutic use

Treatment or prevention of hypokalemia.

Pregnancy and lactiation implications

Unlabeled use


Severe renal impairment, untreated Addison’s disease, heat cramps, hyperkalemia, severe tissue trauma. Solid oral dosage forms contraindicated in patients with delay or arrest in passage through the gastrointestinal tract.

Warnings and precautions

May cause gastrointestinal upset and lead to GI ulceration, bleeding, perforation and/or obstruction. Oral liquid preparations (not solid) should be used in esophageal compression or delayed gastric emptying. Severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (e.g. heart block, ventricular arrhythmias, asystole). Changes in serum potassium concentrations can occur during acid/base correction (use with caution in acid/base alterations). Patients may be more susceptible to life-threatening cardiac effects associated with hyper-/hypokalemia (use with caution in cardiovascular disease (e.g. heart failure, cardiac arrhythmias)). Use with caution in disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (e.g. untreated Addison’s disease, heat cramps, severe tissue breakdown from trauma or burns). Use with caution in renal impairment (contraindicated with severe impairment), in digitalized patients (may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations), and in patients receiving concomitant medications or therapies which increase potassium (e.g. ACEI, potassium-sparing diuretics, potassium-containing salt substitutes).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart